Aurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also developing weight loss drugs. Future growth will come from more product launches and a recent acquisition. Backward integration projects are also boosting profitability. The company expects strong earnings growth.
Multi-asset allocation mutual funds: Nippon India, HDFC feature among SIP top performers and laggards
Systematic investment plans (SIPs) across major equity fund categories have delivered returns over the past two years even as most benchmark indices struggled during the